ClinicalTrials.gg
CompletedNCT03271177PRAGMATICUpdated Sep 1, 2017

Ultrasound Comparison of Radial Artery Hyperplasia After Use of a 7F Sheathless Guide vs. 6F Sheath/Guide Combination

An interventional study of 7F sheathless Guide Catheter and 6F Sheath/Guide Catheter Combination in Coronary Artery Disease, sponsored by Tallahassee Research Institute, Inc.. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-01.

Sponsored by Tallahassee Research Institute, Inc. · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Feb 2016, registered Aug 2017).
Phase
Not applicable
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine if the routine use of a sheathless 7F guide catheter for transradial percutaneous coronary intervention (TR PCI) is non-inferior to a 6F sheath/guide combination with regards to radial artery injury (radial artery intimal-medial-adventitial thickening). To evaluate the radial artery, ultrahigh resolution ultrasonography (55 mHz) will be used to accurately quantify radial artery intimal-medial-adventitial thickness (IMT) at baseline and 90 days. A non-inferiority analysis will be performed to compare the degree of radial artery IMT at 90 days between the 7F sheathless guide approach and the 6F sheath/guide combination.

Read the detailed description

The purpose of the PRAGMATIC study (A Prospective Randomized Trial comparing Radial Artery Intimal Hyperplasia resulting from a 7F Transradial Sheathless Guide [Mach 1] vs. a 6F Transradial Sheath/Guide Combination in Coronary Intervention) is 3 fold: (1) to determine if the routine use of a simple inexpensive "home-made" 7F sheathless guide catheter approach for TRA-PCI was associated with comparable degrees of radial artery access site injury and intimal-medial thickening (IMT) as the routine use of a 6F standard sheath/guide catheter combination; (2) to determine if the 7F sheathless approach was associated with comparable procedural success rates, procedure times, number of guides and crossover rates to a femoral approach compared to a 6F sheath/guide combination; and (3) to use ultrahigh resolution ultrasound to characterize the degree of RA injury and intimal-medial hyperplasia (IMT) that routinely occurs following transradial percutaneous coronary intervention.

Materials and Methods

Subjects and Study Design The study enrolled 41 consecutive patients undergoing elective non-emergent TRA-PCI at Tallahassee Memorial Hospital (TMH) from June 2016 to December 2016. The study protocol was approved by the TMH institutional review board. Informed consent was obtained prior to diagnostic coronary arteriography. Patients aged 21 years and over who were undergoing planned non-emergent PCI and willing to undergo a 24 hour and 90day post PCI RA ultrasound were eligible. Patients were excluded if they had undergone a prior ipsilateral TRA heart catheterization or PCI. There were no angiographic exclusions. Baseline clinical, demographic and angiographic characteristics were collected prospectively. Patients were randomly assigned to undergo TRA-PCI using a 7F sheathless Mach 1TM (Boston Scientific, Marlborough, MA) guide catheter or using our catheterization lab's standard 6F CordisTM (Johnson and Johnson, Inc.) sheath/6F Mach1TM guide combination. In order to minimize radial artery size bias, randomization was stratified according to patient sex. PCI with a drug-eluting stent was performed according to routine local practice and physician discretion. Patients were preferentially treated with a SYNERGYTM (Boston Scientific, Marlborough, MA) drug-eluting stent as the primary stent choice, however, other stents were allowed according to physician discretion.

All patients received dual antiplatelet therapy (DAPT) prior to TRA-PCI with an oral aspirin (325 mg) and a p2Y12 platelet inhibitor (either 600mg clopidogrel or 180mg ticagrelor) bolus. Intravenous heparin was administered to achieve an activated clotting time (ACT) of at least 300 seconds. Immediately following TRA-PCI, the sheath and/or guide was removed and RA hemostasis was achieved using a standardized and previously validated patent hemostasis protocol that incorporates the Terumo TR Band Radial Compression DeviceTM.

The technique used for the sheathless introduction of the 7F guide catheter was as follows: following diagnostic coronary angiography, a 6F 100 cm length multipurpose catheter (MP) was telescoped through the inner lumen of a 90 cm 7F Mach 1TM guide catheter. The MP was then used as an obturator to facilitate insertion of the 7F guide through the skin and into the RA arteriotomy site over a 0.035 J wire. Only after the 7F guide/6F MP combination was introduced into the RA and advanced together back to the aortic root, were the inner 6F MP catheter and 0.035 wire removed and the 7F guide engaged into the coronary ostium for TRA-PCI.

Ultrahigh Resolution Ultrasound Assessment Using the FDA approved FUJIFILM VisualSonics 55 mHz probe and previously established methods,16,17 ultrahigh resolution duplex ultrasound of the RA access site was performed at 24 hours (pre-discharge) and 90 days post TRA-PCI. This technique has been well validated as a means to accurately depict and quantify the individual layers of muscular and elastic arteries. To prevent RA vasospasm, sublingual nitroglycerin (0.4 mg) was administered within 3-5 minutes prior to performing the ultrasound studies. M-mode, 2-dimensional and color doppler images were obtained. The RA diameter was recorded and then the individual borders of the layers of the artery delineated with M-mode ultrasound. To determine the mean IMT, we started off with the center of the probe centered over the RA puncture site and recorded the thickest IMT measurements noted just proximal to the site, at the center of the site (center of probe) and just distal to the site. We then repositioned the probe more proximally, placing its distal leading edge at the puncture site and obtained another proximal and mid probe measurement of IMT. The final recorded IMT was the average of these 5 measurements. Using this technique, we ensured sampling over an adequate length of the RA proximal to, at and slightly distal to the point of arterial access.

The RA access site was also assessed for other signs of trauma, including small focal intimal tears, frank arterial dissections, pseudoaneurysms, arteriovenous fistulae, and vessel occlusion. Given high resolution imaging, we were forced to distinguish between limited focal intimal tears that were now easily visualized and simply a result of access site entry from more frank dissections. For this, we defined a limited access site intimal tear (LASIT) as a focal tear in the intima that was restricted to and not beyond the access site itself which did not encroach on the lumen or cause any flow abnormality. Tears or dissections beyond this were deemed true dissections. All studies and measurements were performed by 2 experienced vascular technicians who were blinded to treatment allocation with additional independent review by a reading physician who was also blinded to treatment allocation.

Other Clinical Endpoints Assessed:

Procedural success rates (successful implantation of the stent with residual stenosis of \< 30% and no other complications), fluoroscopy time, the number of guide catheters used, and the frequency of cross-over from radial access to femoral access were also recorded. Routine clinical and interventional outcomes, including PCI success, in-hospital death, MI, coronary dissection, urgent revascularization were also prospectively collected. Ultrahigh frequency ultrasound parameters related

Statistical Analysis For comparisons between groups, two-sided Student t-tests were used for continuous variables and chi-square or Fisher exact tests for discrete variables. The primary outcome of the study was a comparison of radial artery IMT thickness at 90 days between the 7F sheathless guide catheter group and the standard 6F sheath/guide combination group. The primary statistical analysis was based on a non-inferiority analysis and an intention to treat design. The null hypothesis was that the 7F sheathless Mach 1TM guide would be associated with at least a 0.08mm increase in IMT at 90 days compared with the 6F sheath/guide combination. A non-inferiority margin of 0.08 mm was selected as this represented a relatively small change compared to baseline IMT and RA diameter (\~25% of baseline IMT and only \~3% of RA diameter). It was therefore deemed unlikely that this small difference would be clinically significant. Based on our own pilot data and a prior study, a standard deviation of 0.08mm was assumed for IMT measurements. Assuming a one-sided 95% confidence interval, at least 36 evaluated patients (\~18 per group) were needed to have 90% power to detect if the lower limit of the one-sided confidence interval lies above the 0.08 limit. If the 95% confidence interval lies below this 0.08mm boundary, then the null hypothesis was to be rejected and non-inferiority declared. Superiority testing was also applied using a p\<0.05 for a level of significance for intergroup comparisons.

02

Conditions studied

  • Coronary Artery Disease

Keywords

  • transradial percutaneous coronary intervention
03

In context

Coronary Artery Disease

4,857 studies on the registry are indexed under Coronary Artery Disease; 890 are open to participants now.

This study's enrollment of 41 is below the median of 124 across 3,006 interventional studies indexed under Coronary Artery Disease.

Browse Coronary Artery Disease studies →

Lead sponsor

Tallahassee Research Institute, Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 or above with coronary artery disease
  • Scheduled for transradial PCI

Exclusion criteria

Exclusion Criteria:

  • Has had prior transradial access for heart catheterization or PCI in same radial artery as planned access site
  • Not willing to undergo follow-up ultrasound examinations
  • Acute ST elevation myocardial infarction or other emergent PCI
  • Inability to provide
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    7F Sheathless Guide Catheter

    Patients in this arm will undergo their percutaneous coronary intervention using a 7F Sheathless guide catheter

    Device: 7F sheathless Guide Catheter

  • Placebo comparator
    6F Sheath/Guide Catheter Combination

    Patients in this arm will undergo their percutaneous coronary intervention using a 6F Sheath/guide combination

    Device: 6F Sheath/Guide Catheter Combination

Interventions

  • Device7F sheathless Guide Catheter

    Transradial PCI will be performed with a 7F sheathless Guide Catheter

  • Device6F Sheath/Guide Catheter Combination

    Transradial PCI will be performed with a 6F Sheath/Guide Catheter Combination

06

What researchers measure

Primary outcomes

  1. Radial artery access site intimal-medial thickness (IMT)

    The incidence of other vascular complications such as radial artery occlusion, pseudo-aneurysms, radial artery diameter, and radial artery dissections will also be assessed.

    Time frame: 90-day

Secondary outcomes

  1. Procedural Success Rate

    Procedural Success Rate (successful coronary stent implantation with \< 30% residual stenosis and no other complications)

    Time frame: up to 24 hours

  2. Major Adverse Cardiac Events (MACE)

    In-hospital MACE (death, MI, urgent revascularization)

    Time frame: from date of PCI until date of death, MI or urgent revascularization, whichever came first, assessed up to 72 hrs

  3. Fluoroscopy Time

    Fluoroscopy Time

    Time frame: During PCI procedure (from beginning of procedure until end)

  4. Number of Guide Catheters Used

    Number of Guide Catheters Used during the procedure

    Time frame: During PCI procedure (from beginning of procedure until end)

  5. Frequency of Cross-over from Radial Access to Femoral Access

    Rate of Needing to Cross-over from Radial Access to Femoral Access

    Time frame: During PCI procedure (from beginning of procedure until end)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2016 to primary completion in Mar 2017, 12 months.

Of 753 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's 12 months is below that.

Counting every sponsor, half of 930 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2017
First posted
Sep 1, 2017
StartActual
Feb 25, 2016
Primary completionActual
Mar 13, 2017
CompletionActual
Mar 13, 2017
Last update
Sep 1, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03271177
Lead sponsor
Tallahassee Research Institute, Inc.
Responsible party
Sponsor
First posted
Sep 1, 2017
Start date
Feb 25, 2016
Primary completion
Mar 13, 2017
Completion
Mar 13, 2017
Last update
Sep 1, 2017

Study contacts

Wayne B Batchelor, MD, MHS
principal investigator · Tallahassee Research Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion